

**FAKULTAS KEDOKTERAN
UNIVERSITAS PEMBANGUNAN NASIONAL “VETERAN” JAKARTA**

Skripsi, November 2025

WYANDA PUAN PALARTI JUBAIR HEGEMUR, 2210211234

**ANALISIS PENGARUH DURASI PEMBERIAN OBAT
ANTIRETROVIRAL LINI I TERHADAP KADAR CD4+ PADA PASIEN
DEWASA HIV DI RS PELNI JAKARTA TAHUN 2023-2024**

(CIII + 103 halaman, 16 tabel, 5 gambar, 12 lampiran)

ABSTRAK

Tujuan

Tingginya kasus HIV/AIDS di Indonesia, khususnya di DKI Jakarta, menegaskan pentingnya pemantauan terapi antiretroviral (ARV) dalam meningkatkan status imunologis pasien. Gangguan imun pada pasien HIV terjadi akibat penurunan progresif sel CD4+. Penelitian ini bertujuan menganalisis pengaruh durasi pemberian ARV lini 1 terhadap peningkatan kadar limfosit CD4+ pada pasien dewasa dengan HIV selama periode 2023–2024.

Metode

Penelitian *cross-sectional* menggunakan jenis analitik observasional dengan teknik simple random sampling terhadap populasi pasien HIV selama Januari 2023–Desember 2024 sehingga didapatkan 50 rekam medis.

Hasil

Dari 50 data rekam medis, Sebelum pengobatan ARV rata-rata kadar CD4+ sebesar 118,36 sel/mm³. Setelah 6 dan 12 bulan kadar CD4+ mengalami peningkatan pada pemberian obat ARV lini 1 selama 6 dan 12 bulan. Selama 6 bulan rata-rata kadar CD4+ sebesar 256.88 sel/mm³ dan pada 12 bulan sebesar 335.78 sel/mm³. Analisis bivariat dengan uji Wilcoxon sebagai alternatif uji T test dependent serta besaran dengan Prevalence Odds Ratio (POR) menunjukkan $p = 0.000$.

Kesimpulan

Dengan dasar hasil penelitian, dapat disimpulkan bahwa adanya hubungan yang signifikan antara durasi pemberian antiretroviral (ARV) lini 1 terhadap peningkatan kadar CD4+ pasien HIV.

Daftar Pustaka : 58 (2015-2025)

Kata Kunci : Antiretroviral (ARV), Imunologi, Kadar CD4+, HIV

FACULTY OF MEDICINE

UNIVERSITY PEMBANGUNAN NASIONAL “VETERAN” JAKARTA

Undergraduate Thesis, November 2025

WYANDA PUAN PALARTI JUBAIR HEGEMUR, 2210211234

**ANALYSIS OF THE EFFECT OF DURATION OF FIRST-LINE
ANTIRETROVIRAL DRUG ADMINISTRATION ON CD4+ LEVELS IN
ADULT HIV PATIENTS AT PELNI HOSPITAL JAKARTA IN 2023-2024**

(CIII + 103 pages, 16 tables, 5 pictures, 12 appendices)

ABSTRACT

Objective

The high incidence of HIV/AIDS in Indonesia, particularly in DKI Jakarta, emphasizes the importance of monitoring antiretroviral (ARV) therapy to improve patients' immunological status. Immune dysfunction in HIV patients occurs due to the progressive decline of CD4+ cells. This study aims to analyze the effect of the duration of first-line ARV administration on the increase of CD4+ lymphocyte levels in adult HIV patients during the 2023–2024 period.

Method

The cross-sectional study used an observational analytic type with a simple random sampling technique on the population of HIV patients from January 2023 to December 2024, resulting in 50 medical records.

Result

From 50 medical record data, before ARV treatment, the average CD4+ count was 118.36 cells/mm³, and after 6 and 12 months, the CD4+ count increased with the administration of first-line ARV drugs over 6 and 12 months. At 6 months, the average CD4+ count was 256.88 cells/mm³, and at 12 months it was 335.78 cells/mm³. Bivariate analysis using the Wilcoxon test as an alternative to the

dependent T-test and the measure with Prevalence Odds Ratio (POR) showed $p = 0.000$.

Conclusion

Based on the research results, it can be concluded that there is a significant relationship between the duration of first-line antiretroviral (ARV) therapy and the increase in CD4+ levels in HIV patients.

Reference : 58 (2015-2025)

Keywords : Antiretroviral (ARV), Immunology, CD4+ levels, HIV